Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2011 May 26;364(21):2055-8.
doi: 10.1056/NEJMe1102758.

Expanding treatment options for metastatic prostate cancer

Emmanuel S Antonarakis, Mario A Eisenberger
Editorial

Expanding treatment options for metastatic prostate cancer

Emmanuel S Antonarakis et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Evidence-Based Therapies for Metastatic Castration-Resistant Prostate Cancer, and Selected Emerging Treatments
Radionuclide bone scans show the typical progression of metastatic castration-resistant prostate cancer from limited bone involvement (left) to progressive bone metastases (middle) to extensive metastases (right). The computed tomographic scans on the far right show visceral (lung and liver) metastases. Green boxes indicate agents that are currently approved by the Food and Drug Administration for the treatment of metastatic castration-resistant prostate cancer. The effects of these agents on disease progression and overall survival are shown. Orange boxes indicate selected agents currently in phase 3 drug development.
See this image and copyright information in PMC

Comment in

Comment on

  • Abiraterone and increased survival in metastatic prostate cancer.
    de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. de Bono JS, et al. N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618. N Engl J Med. 2011. PMID: 21612468 Free PMC article. Clinical Trial.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141–9. - PMC - PubMed
    1. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res. 2009;15:4792–8. - PMC - PubMed
    1. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. - PMC - PubMed
    1. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583) J Clin Oncol. 2004;22:1025–33. - PubMed
    1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. - PubMed

MeSH terms